ConductScience.org, home

Paper1968358

Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.

Ford JM and 4 others. Cancer Res, 1990. Cited by 147 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Papers, record 1968358. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1968358

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
PubMed
Journal
Cancer Res
PubMed
Year
1990
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
147
iCite
Relative citation ratio, by iCite
4.99
iCite
Revised in PubMed
2018-11-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ford JMJ M
2Bruggemann EPE P
3Pastan II
4Gottesman MMM M
5Hait WNW N

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug ResistanceMajor topic
Membrane GlycoproteinsMajor topic
ThioxanthenesMajor topic
ATP Binding Cassette Transporter, Subfamily B, Member 1
Animals
Breast Neoplasms
Calmodulin
Cell Division
Cell Line
Cell Membrane
Cells, Cultured
Humans
KB Cells
Mice
Neoplasm Proteins
Protein Kinase C
Structure-Activity Relationship
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA43888-03NCI NIH HHSUnited StatesPubMedPubMed
P01 CA08341-25NCI NIH HHSUnited StatesP01CA083412PubMedNIH RePORTER
P01CA008341NIHNIH RePORTER
R01CA043888NIHNIH RePORTER

Download CSV of grants

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 147 citations.

PMIDTitleJournalYearIn PapersSource
38524477Intramolecular Friedel-Crafts Reaction with Trifluoroacetic Acid: Synthesizing Some New Functionalized 9-Aryl/Alkyl Thioxanthenes.ACS Omega2024https://conductscience.org/library/papers/38524477PubMed
30813251The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells.Int J Mol Sci2019https://conductscience.org/library/papers/30813251PubMed
25801244Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.Tumour Biol2015https://conductscience.org/library/papers/25801244PubMed
24944704Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells.Oncol Lett2014https://conductscience.org/library/papers/24944704PubMed
24641346Multilayer spheroids to quantify drug uptake and diffusion in 3D.Mol Pharm2014https://conductscience.org/library/papers/24641346PubMed
23973912Nanopreparations to overcome multidrug resistance in cancer.Adv Drug Deliv Rev2013https://conductscience.org/library/papers/23973912PubMed
22363694High glucose decreases expression and activity of p-glycoprotein in cultured human retinal pigment epithelium possibly through iNOS induction.PLoS One2012https://conductscience.org/library/papers/22363694PubMed
20520719Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.PLoS One2010https://conductscience.org/library/papers/20520719PubMed
19533022Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.Invest New Drugs2010https://conductscience.org/library/papers/19533022PubMed
18945821Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.Mol Pharmacol2009https://conductscience.org/library/papers/18945821PubMed
18493718Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).Invest New Drugs2009https://conductscience.org/library/papers/18493718PubMed
14586208Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells.Invest New Drugs2003https://conductscience.org/library/papers/14586208PubMed
12543683Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus.Antimicrob Agents Chemother2003https://conductscience.org/library/papers/12543683PubMed
11934808Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.Br J Pharmacol2002https://conductscience.org/library/papers/11934808PubMed
11434876Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.Breast Cancer Res2001https://conductscience.org/library/papers/11434876PubMed
9380680Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.Proc Natl Acad Sci U S A1997https://conductscience.org/library/papers/9380680PubMed
8738607Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.Breast Cancer Res Treat1996https://conductscience.org/library/papers/8738607PubMed
8546900MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.Br J Cancer1996https://conductscience.org/library/papers/8546900PubMed
8543589Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8543589PubMed
8431967Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8431967PubMed

See all 23 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
CALM1801PubTator's text mininghttps://conductscience.org/library/genes/801NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1968358

GET https://conductscience.org/api/papers/v1/1968358/cited_by?page=2